Trading Animal Models for Patient-Derived Precision

Can Human Tumor Fragments Replace Mouse Studies?

Update: The NIH announced it will NO LONGER fund new studies that rely solely on animal testing! More here.

The FDA’s recent initiatives (Modernization Act 2.0 in Dec. 2022 and a 2025 roadmap) signal a major paradigm shift. Regulators now encourage New Approach Methodologies (NAMs), including human cell assays, organoids, organ-on-chip systems and AI – for IND applications. FDA leadership envisions “replacing animal testing” with human-relevant methods to improve safety predictivity and speed up drug development. This momentum raises a provocative question for biotech innovators: Could ex vivo human tumor fragments (patient-derived organoids/slices) one day stand in for mouse models in oncology R&D?

Advantages of ex vivo tumor cultures: Unlike mouse xenografts, cultured human tumor fragments preserve native 3D architecture, cellular diversity and microenvironmental cues. This human relevance can yield more predictive pharmacology: rodent models miss key human-specific drug responses (ge…